A group of federal health agencies is reaffirming its interest in supporting research that explores the therapeutic potential of “minor cannabinoids” and terpenes in marijuana.
The National Institutes of Health (NIH) and eight of its component agencies posted a notice of special interest (NOSI) last week, titled “Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes.”
Minor cannabinoids are defined as the constituents of marijuana except delta-9 THC, the most commonly known and studied intoxicating compound in cannabis. NIH said that research into the lesser-known cannabinoids like delta-8 THC, CBN and CBG, as well as terpenes, is comparatively lacking.
“This NOSI intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to investigate the impact of minor cannabinoids and terpenes on mechanisms underlying their therapeutic effects,” the notice says. “Preclinical studies of combinations of minor cannabinoids with terpenes or other natural products that may enhance their therapeutic benefits and/or abate unwanted effects are encouraged.”
“The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to symptoms relief and functional restoration may be very broad encompassing different pathological conditions and diseases. This NOSI encourages interdisciplinary collaborations among
Read full article on Marijuana Moment
